RDB05553 - CSII-CMV-Venus

Resource data sheet
Prev. | Lentiviral vector plasmid >
Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

CSII-CMV-Venus

Lentivirus vector plasmid of Venus fluorescent protein driven by CMV promoter.

Catalog number	RDB05553
Resource name	CSII-CMV-Venus
Clone info.	Lentivirus vector plasmid of Venus fluorescent protein driven by CMV promoter.
Comment	Commonly requested with pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Vector backbone	CSII-CMV-MCS (Plasmid)
Selectable markers	Please note that Zeo resistance marker is not included in the lentivirus produced from this vector. E. coli: Amp^r.
Gene/insert name	Aequorea victoria GFP cDNA
Depositor\|Developer	Miyoshi, Hiroyuki \|

Other clones in our bank

External Database
Aequorea victoria GFP

Reference sequence

Lentiviral plasmid list. [link]

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.

Additional terms and conditions for distribution RECIPIENT is requested to obtain written consent of Dr. Atsushi Miyawaki of the RIKEN CBS regarding Venus fluorescent protein.

Ordering Please visit Ordering instruction.[link]
Order form [Credit Card Payment] [Bank Transfer Payment]
Material Transfer Agreement (MTA, for use for not-for-profit academic purpose)[Word]
Approval form [Word] by Dr. Atsushi Miyawaki

Remarks ((Remarks)) Remember that you will be working with samples containing infectious virus.
Please contact us. We will provide you with appropriate documents.
Please obtain written approval of Dr. Atsushi Miyawaki.

提供案内 (日本国内) [open/close]

Terms and conditions set forth by the DEPOSITOR	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.
Additional terms and conditions for distribution	RECIPIENT is requested to obtain written consent of Dr. Atsushi Miyawaki of the RIKEN CBS regarding Venus fluorescent protein.
Ordering	Please visit Ordering instruction.[link] Order form [Credit Card Payment] [Bank Transfer Payment] Material Transfer Agreement (MTA, for use for not-for-profit academic purpose)[Word] Approval form [Word] by Dr. Atsushi Miyawaki
Remarks	((Remarks)) Remember that you will be working with samples containing infectious virus. Please contact us. We will provide you with appropriate documents. Please obtain written approval of Dr. Atsushi Miyawaki.

提供条件	本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。
付加的提供条件	利用者は、Venus蛍光タンパク質について理化学研究所CBS 宮脇敦史博士から、書面による提供承諾を得ること。
提供依頼	手続きの詳細は、「レンチウイルスベクターの提供申し込み」をご覧ください。提供依頼書 [Word] 提供同意書 (非営利機関による非営利学術研究用)[Word] 遺伝子組換え生物の受入れ確認書が必要です。当室にご請求ください。宮脇敦史博士による提供承諾書 [Word]
備考	【使用上の注意】このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。宮脇敦史博士の書面による提供承諾が必要です。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB05553	CSII-CMV-Venus	DNA solution

Ordering instruction of plasmids [in Japanese] [in English]
Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

References and tips

Electronic file

Sequence	RDB05553z.seq
Remarks, protocol and/or map (pdf)	RDB05553.pdf

Original reference

Further references such as user reports and related articles (go to bottom)

Sequence information

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB12356_A4Afp1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: CSII-CMV5' Sequence file: RDB12356_A4Afa.seq
>05553_12356_A4Af_CSII-CMV5'_A02_02.ab1 1 ACGGCAACGC TCGGTCTCGA GATTCTGCAG CGGCCGCGGA TCCACCATGG TGAGCAAGGG 61 CGAGGAGCTG TTCACCGGGG TGGTGCCCAT CCTGGTCGAG CTGGACGGCG ACGTAAACGG 121 CCACAAGTTC AGCGTGTCCG GCGAGGGCGA GGGCGATGCC ACCTACGGCA AGCTGACCCT 181 GAAGCTGATC TGCACCACCG GCAAGCTGCC CGTGCCCTGG CCCACCCTCG TGACCACCCT 241 GGGCTACGGC CTGCAGTGCT TCGCCCGCTA CCCCGACCAC ATGAAGCAGC ACGACTTCTT 301 CAAGTCCGCC ATGCCCGAAG GCTACGTCCA GGAGCGCACC ATCTTCTTCA AGGACGACGG 361 CAACTACAAG ACCCGCGCCG AGGTGAAGTT CGAGGGCGAC ACCCTGGTGA ACCGCATCGA 421 GCTGAAGGGC ATCGACTTCA AGGAGGACGG CAACATCCTG GGGCACAAGC TGGAGTACAA 481 CTACAACAGC CACAACGTCT ATATCACCGC CGACAAGCAG AAGAACGGCA TCAAGGCCAA 541 CTTCAAGATC CGCCACAACA TCGAGGACGG CGGCGTGCAG CTCGCCGACC ACTACCAGCA 601 GAACACCCCC ATCGGCGACG GCCCCGTGCT GCTGCCCGAC AACCACTACC TGAGCTACCA 661 GTCCGCCCTG AGCAAAGACC CCAACGAGAA GCGCGATCAC ATGGTCCTGC TGGAGTTCGT 721 GACCGCCGCC GGGATCACTC TCGGCATGGA CGAGCTGTAC AAGTAAGAAT TCAAGGCCTC 781 TCGAGCCTCT AGAGTTAACA TCGAGGGATC AAGCTTATCG ATAATCAACC TCTGGATTAC 841 AAAATTTGTG AAAGATTGAC TGGTATTCTT AACTATGTTG CTCCTTTTAC GCTATGTGGA 901 TACGCTGCTT TAATGCCTTT GTATCATGCT ATTGCTTCCC GTATGGCTTT CATTTTCTCC 961 TCCTTGTATA AATCCTGGTT GCTGTCTCTT TATGAGGAGT TGTGGCCCGT TGTCAGCAAC 1021 GTGGCGTGTG TGCACTGTGT TTGCTGACGC ACCCCCACTG GTTGGGGGCA TTGCACACTG 1081 TCAGCTCCTT TTCCAGACTT TCGCTTTCCC CCACCTATTG CCACGGCGGA AACTTCATTC 1141 CGCCCGCCCT GTG //
Primer: HIVgp_R1 Sequence file: RDB12356_A4Afb.seq
>05553_12356_A4Af_HIVgp_R1_B02_05.ab1 1 CCAGCTCTAT TCCACTGCTC TTTTTTCTCT CTGCACCACT CTTCTCTTTG CCTTGGTGGG 61 TGCTACTCCT AATGGTTCAA TTTTTACTAC TTTATATTTA TATAATTCAC TTCTCCAATT 121 GTCCCTCATA TCTCCTCCTC CAGGTCTGAA GATCAGCGGC CGGCCGCTTG CTGTGCGGTG 181 GTCTTACTTT TGTTTTGCTC TTCCTCTATC TTGTCTAAAG CTTCCTTGGT GTCTTTTATC 241 TCTATCCTTT GATGCACACA ATAGAGGGTT GCTACTGTAT TATATAATGA TCTAAGTTCT 301 TCTGATCCTG TCTGAAGGGA TGGTTGTAGC TGTCCCAGTA TTTGTCTACA GCCTTCTGAT 361 GTTTCTAACA GGCCAGGATT AACTGCGAAT CGTTCTAGCT CCCTGCTTGC CCATACTATA 421 TGTTTTAATT TATATTTTTT CTTTCCCCCT GGCCTTAACC GAATTTTTTC CCATCGCGAT 481 CTAATTCTCC CCCGCTTAAT ACTGACGCTC TCGCACCCAT CTCTCTCCTT CTAGCCTCCG 541 CTAGTCAAAA TTTTTGGCGT ACTCACCAGT CGCCGCCCCT CGCCTCTTGC CGTGCGCGCT 601 TCAGCAAGCC GAGTCCTGCG TCGAGAGAGC TCCTCTGGTT TCCCTTTCGC TTTCAAGTCC 661 CTGTTCGGGC GCCACTGCTA GAGATTTTCC ACACTGACTA AAAGGGTCTG AGGGATCTCT 721 AGTTACCAGA GTCACACAAC AGACGGGCAC ACACTACTTG AAGCACTCAA GGCAAGCTTT 781 ATTGAGGCTT AAGCAGTGGG TTCCCTAGTT AGCCAGAGAG CTCCCAGGCT CAGATCTGGT 841 CTAACCAGAG AGACCCAGTA CAGGCAAAAC GCGCTGCTTA TATAGACCTC CCACCGTACA 901 CGCCTACCGC CCATTTGCGT CAATGGGGCG GAGTTGTTAC GACATTTTGG AAAGTCCCGT 961 TGATTTTGGT GCCAAAACAA ACTCCCATTG ACGTCAATGG GGTGGAGACT TGGAAATCCC 1021 CGTGAGTCAA CCGCTATCCA CGCCCATTGA TGTACTGCCA AAACCGCATC ACCATGGTAA 1081 TAGCGATGAC TAATACGTAG ATGTACTGCC AAGTAAGAAG TCCATACGTT CAATGTACTG 1141 GGCATAATGC CAGGCGGGGC CCAATTTTAA CCCGGTTCCA TTTGAA //
Primer: BGH_rev Sequence file: RDB12356_A4Afc.seq
>05553_12356_A4Af_BGHrev_C02_08.ab1 1 GTTACGGGTC TGCTAGAGAT TTTCCACACT GACTAAAAGG GTCTGAGGGA TCTCTAGTTA 61 CCAGAGTCAC ACAACAGACG GGCACACACT ACTTGAAGCA CTCAAGGCAA GCTTTATTGA 121 GGCTTAAGCA GTGGGTTCCC TAGTTAGCCA GAGAGCTCCC AGGCTCAGAT CTGGTCTAAC 181 CAGAGAGACC CAGTACAGTC CGGATGCAGC TCTCGGGCCA TGTGATGAAA TGCTAGGCGG 241 CTGTCAAACC TCCACTCTAA TACTTCTCTC TCCGGGTCAT CCATCCCATG CAGGCTCACA 301 GGGTGTAACA AGCGGGTGTT CTCTCCTTCA TTGGCTTCTT CTACCTTCTC TTGCTCAACT 361 GGTACTAGCT TGTAGCACCA TCCAAAGGTC AGTGGATATC TGATCCCTGG CCCTGGTGTG 421 TAGTTCTGCC AATCAGGGAA GTAGCCTTGT GTGTGGTAGA TCCACAGATC AAGGATATCT 481 TGTCTTCGTT GGGAGTGAAT TAGCCCTTCC AGTCCCCCCT TTTCTTTTAA AAAGTGGCTA 541 AGATCTACAG CTGCCTTGTA AGTCATTGGT CTTAAAGGTA CCTGAGGTGT GACTGGAAAA 601 CCCACCTCCT CCTCCTCTTG TGCTTCTAGC CAGGCACAAT CAGCATTGGT AGCTGCTGTA 661 TTGCTACTTG TGATTGCTCC ATGTTTTTCT AGGTCTCGAC GGTATCGATG CGGGGAGGCG 721 GCCCAAAGGG AGATCCGACT CGTCTGAGGG CGAAGGCGAA GACGCGGAAG AGGCCGCAGA 781 GCCGGCAGCA GGCCGCGGGA AGGAAGGTCC GCTGGATTGA GGGCCGAAGG GACGTAGCAG 841 AAGGACGTCC CGCGCAGAAT CCAGGTGGCA ACACAGGCGA GCAGCCATGG AAAGGACGTC 901 AGCTTCCCCG ACAACACCAC GGAATTGTCA GTGCCCAACA GCCGAGCCTC CTGTCCAGCA 961 GCGGGCAAAG GCAGGCGGCG ATGAGTTCCG CCGTGGCAAT AGGGAGGGGG AAAGCGAAAG 1021 TCCTCGGGAA GGGAGCTGAC AGGTGGTGGC AATGCCTCCA ACTCAGTGGG GGGGTTGCGT 1081 CAGCAAACAC AGTGCACCAT CACGTCACGT TGCCTGACAC GGGCCACACT TCTCATAAGA 1141 AGACAGCCAC CAGGAATTTA TACACGGGAG GGGAGGAAAA ATTGAAAGGT CTCAATATAC 1201 CG //
Primer: SV40pro_F Sequence file: RDB12356_A4Afd.seq
>05553_12356_A4Af_SV40pro_F_D02_11.ab1 1 CCCTGGTCGT GGCATTCAGA GTAGTGAGGA GGCTTTTTTG GAGGCCTAGG CTTTTGCAAA 61 AAGCTCCCGG GAGCTTGTAT ATCCATTTTC GGATCTGATC AGCACGTGTT GACAATTAAT 121 CATCGGCATA GTATATCGGC ATAGTATAAT ACGACAAGGT GAGGAACTAA ACCATGGCCA 181 AGTTGACCAG TGCCGTTCCG GTGCTCACCG CGCGCGACGT CGCCGGAGCG GTCGAGTTCT 241 GGACCGACCG GCTCGGGTTC TCCCGGGACT TCGTGGAGGA CGACTTCGCC GGTGTGGTCC 301 GGGACGACGT GACCCTGTTC ATCAGCGCGG TCCAGGACCA GGTGGTGCCG GACAACACCC 361 TGGCCTGGGT GTGGGTGCGC GGCCTGGACG AGCTGTACGC CGAGTGGTCG GAGGTCGTGT 421 CCACGAACTT CCGGGACGCC TCCGGGCCGG CCATGACCGA GATCGGCGAG CAGCCGTGGG 481 GGCGGGAGTT CGCCCTGCGC GACCCGGCCG GCAACTGCGT GCACTTCGTG GCCGAGGAGC 541 AGGACTGACA CGTGCTACGA GATTTCGATT CCACCGCCGC CTTCTATGAA AGGTTGGGCT 601 TCGGAATCGT TTTCCGGGAC GCCGGCTGGA TGATCCTCCA GCGCGGGGAT CTCATGCTGG 661 AGTTCTTCGC CCACCCCAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA 721 GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA 781 AACTCATCAA TGTATCTTAT CATGTCTGTA TACCGTCGAC CTCTAGCTAG AGCTTGGCGT 841 AATCATGGTC ATAGCTGTTT CCTGTGTGAA ATTGTTATCC GCTCACAATT CCACACAACA 901 TACGAGCCGG AAGCATAAAG TGTAAAGCCT GGGGTGCCTA ATGAGTGAGC TAACTCACAT 961 TAATTGCGTT GCGCTCACTG CCCGCTTTCC AGTCGGGAAA CCTGTCGTGC CAGCTGCATT 1021 AATGAATCGG GCCAACGCGC GGGGGAGAGG CGGGTTTGCG TATTGGGGCG CTCTTTCCGC 1081 CTTCTCGCTC ACTGACTCGC TGCGCTCGCT CGCTCCGCCT GCCGGCCGAG CCGCTATCAG 1141 CCTCACTCCA AAGGCCGGTA ATTACCCGGC TATC //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

user_report	Lu, F., Down-regulated in renal cell carcinoma 1 (DRR1) regulates axon outgrowth during hippocampal neuron development. Biochem. Biophys. Res. Commun. 558: 36-43 (2021). PMID 33895549.
user_report	Mu, P., A novel nuclear complex of DRR1, F-actin and COMMD1 involved in NF-κB degradation and cell growth suppression in neuroblastoma. Oncogene 36 (41): 5745-5756 (2017). PMID 28604741.
user_report	Murakami-Tonami, Y., SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Sci. Rep. 6: 31615 (2016). PMID 27539729.
user_report	Nakaguro, M., Nucleolar protein PES1 is a marker of neuroblastoma outcome and is associated with neuroblastoma differentiation. Cancer Sci. 106 (3): 237-243 (2015). PMID 25557119.
user_report	Murakami-Tonami, Y., Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle 13 (7): 1115-1131 (2014). PMID 24553121.
user_report	Muraoka, N., MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO J., 33 (14): 1565-1581 (2014). PMID 24920580.
user_report	Huang, P., The neuronal differentiation factor NeuroD1 downregulates the neuronal repellent factor Slit2 expression and promotes cell motility and tumor formation of neuroblastoma. Cancer Res., 71 (8), 2938-2948 (2011). PMID 21349947.

2022.05.18

GNP_filter3_RDBDEP_html_220516.pl